BioWorld

July 30, 2008

Rebounding Amgen Trumps Q2 Estimates Despite Profit Decline

Amgen Inc.'s second-quarter earnings outstripped Wall Street expectations and sent shares rising for the second day in a row, signaling a much-needed upturn following a year and a half of negative ESA headlines. (BioWorld Today) Read More

FDA Panel Backs Approval of Roche IL-6 Arthritis Drug

Intercept Gets $25M for Bile Acid Trials

Celator Raises $22.5M for CombiPlex Products Pipeline

Other News To Note

Clinic Roundup

Today's news in brief

BioWorld

BioWorld briefs for Dec. 12, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 12, 2025.

CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials

BioWorld

A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...

Illustration of head with maze that is missing parts

CTAD 2025: The challenges of combination therapies for dementia

BioWorld Science

At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...

Illustration of motor neuron connecting to muscle fiber

Research grants support early clinical trials of ALS treatments

BioWorld Science

The ALS Association has announced the recipients of its 2025 Hoffman ALS Clinical Trial Awards. These research grants, worth up to $1 million each, support...